Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews various treatments for alopecia, highlighting that minoxidil, finasteride, PRP therapy, and hair transplants are the most commonly used options, but it reports no new clinical results.

In this study, researchers found that alopecia areata patients show a significant reduction in suppressive regulatory T-cells and an increase in inflammatory T-cell populations, suggesting an immunological imbalance contributing to the disease.

This study identified a specific genetic variant in the CCHCR1 gene that may contribute to alopecia areata through impaired keratinization, suggesting an alternative mechanism beyond autoimmune causes.

This chapter reviews the skin side effects associated with targeted cancer therapies and emphasizes the importance of collaboration between oncologists and dermatologists without reporting new results.

This chapter reviews the presence and roles of stem cells in various body systems, focusing on their lifelong function in animals and humans, and reports no new experimental findings.

This study reports a novel mutation in the TP63 gene associated with T and B cell lymphopenia in an EEC patient, suggesting that EEC diagnosis should include TREC assay and evaluation for immunodeficiency.

This study found that in a rat model of alopecia, combining low-level laser therapy with Neoptide treatment resulted in better hair regrowth compared to either treatment used alone.

Low-Level Laser Therapy can stimulate healing and cell function, potentially leading to wider medical use.

This study found significant improvements in hair growth parameters and a reduction in hair fall after using the test product for 90 days, with no adverse events reported.

The document concludes that hair analysis is not good for assessing nutrition but can detect long-term heavy metal exposure.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.

This study found that tofacitinib may be effective for treating pediatric rheumatic diseases, with especially promising results in patients with autoinflammatory diseases, arthritis and alopecia, and juvenile dermatomyositis.

This study observed that oral tofacitinib was reasonably well-tolerated but had limited efficacy in treating alopecia areata, with a clinical response seen in 41.4% of patients over six months.

In this six-year study of a Saudi cohort, oral tofacitinib showed favorable long-term effectiveness for patients with AA, with manageable adverse events requiring regular monitoring.

This article presents a toolkit created by the FTA to help transit agencies manage employees' use of medications that could impact public safety, but it reports no new results.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This study found that women with polycystic ovary syndrome have higher triglyceride and fasting glucose levels in obese individuals and higher total cholesterol levels in non-obese individuals compared to healthy women.

The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.

In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.

This study found that oral tofacitinib achieved significant hair regrowth in children with moderate to severe alopecia areata, with 72.2% reaching a 75% improvement and 52.8% achieving complete regrowth, though some patients did not respond and further research is needed on the treatment's long-term effects.

This study found that TAZ promotes adipogenesis in goat adipose-derived mesenchymal stem cells by enhancing PI3K/AKT pathway activity, with overexpression boosting adipocyte formation and knockdown inhibiting it.

In this pilot study, both tofacitinib and methotrexate improved alopecia areata outcomes, but tofacitinib showed greater efficacy in achieving significant SALT score improvement after 6 months, although the difference was not statistically significant.

This article lists the clinically important interactions and skin reactions of several drugs and substances, including THA, FK506, tamoxifen, tamsulosin, tartrazine, tea tree oil, temazepam, and temozolomide, but provides no new clinical results.

In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.

HGF combined with ADA is highly accurate for diagnosing tuberculous pleural effusion, especially in younger females.

This study compared oral tofacitinib and methotrexate in treating moderate-to-severe alopecia areata, finding that tofacitinib was more effective at reducing SALT scores and improving scalp hair assessment PRO scores, though both treatments reduced psychological distress similarly without serious adverse effects.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.